CytoMed shares surge 20.85% premarket after securing $500K non-dilutive investment for LongevityBank subsidiary from ICH Capital.

CytoMed Therapeutics surged 20.85% in premarket trading following two key announcements: securing a non-dilutive $500,000 investment for its subsidiary LongevityBank from ICH Capital, providing a 10% post-money stake to fund autologous cell therapy development, and regulatory progress in China under State Council Decree No. 818, which establishes a streamlined pathway for cell therapies as medical procedures. The investment, non-dilutive nature, and strategic alignment with LongevityBank’s autologous therapies—complementing CytoMed’s allogeneic clinical trials—signal operational diversification and capital efficiency. The Chinese regulatory shift enhances commercialization prospects for its patented gamma delta T cell platform, while collaborations with local firms and patent approvals reinforce competitive positioning. These developments collectively drove optimism about expanded market access and revenue potential.